Ensysce Biosciences, Inc. ENSC
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Ensysce Biosciences, Inc. (ENSC) is a healthcare company listed in the US with a market value of about $8M. In the twelve months to September 30, 2026 it had revenue of $6M and net income of -$91M, a net margin of -1473.7%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 5% a year, a 5-year average ROIC of -956%.
About Ensysce Biosciences
Ensysce Biosciences is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $4M in 2020 to $5M in 2025, growth of about 5.2% a year. It was profitable in 2 of the last 8 years in our data. Its share count rose by 21220% over three years (dilution for shareholders). It spends 205% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6M | $5M | $5M | $2M | $3M | $4M | $4M | — | — |
| Net income | -$91M | -$10M | -$8M | -$11M | -$25M | -$30M | $4M | -$1M | $2M |
| Free cash flow | — | -$8M | — | — | — | — | — | — | — |
| EPS (diluted) | $-2.47 | $-0.50 | $-1.43 | $-8.80 | $-261.41 | $-2.78 | $0.00 | $-1.18 | $-0.39 |
| Net margin | -1473.7% | -200.8% | -153.3% | -476.4% | -994.1% | -846.4% | 109.7% | — | — |
| ROIC | — | -229.8% | -132.6% | -1592.1% | -2659.1% | -168.2% | — | -47.2% | -15.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 3 analysts is $4.08, 876% above the current price; targets range from $2.00 to $8.25; the consensus rating is “Strong buy”; expected EPS is $-0.23 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Ensysce Biosciences pay a dividend?
Not currently.
Is Ensysce Biosciences a good stock to buy?
We do not give buy or sell advice. Ensysce Biosciences scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.